CLRB — Cellectar Biosciences Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Cellectar Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 35.7 | 19.9 | 9.56 | 23.3 | 13.2 |
| Prepaid Expenses | |||||
| Total Current Assets | 36.6 | 20.5 | 10.5 | 24.3 | 14 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.549 | 0.979 | 1.59 | 1.19 | 0.91 |
| Other Long Term Assets | |||||
| Total Assets | 37.2 | 21.6 | 12.1 | 25.5 | 15 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.99 | 5.53 | 12.9 | 9.39 | 4.75 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.16 | 6.08 | 13.4 | 9.8 | 5.06 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 33 | 15.5 | -1.36 | 15.7 | 9.92 |
| Total Liabilities & Shareholders' Equity | 37.2 | 21.6 | 12.1 | 25.5 | 15 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |